The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

Linvoseltamab demonstrated a 79% ORR in newly diagnosed multiple myeloma, with 86% in the 200 mg cohort, indicating robust efficacy. Rapid responses were observed, with a median time to partial ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...

Regarding safety, any-grade adverse events occurred in 100% and 99% of patients on epcoritamab plus R 2 and R 2 alone, with grade 3 or higher AEs at 90% and 68%, respectively. Serious AEs occurred in ...

Azacitidine plus venetoclax (Venclexta) demonstrated significantly improved event-free survival (EFS) vs intensive induction chemotherapy in patients with acute myeloid leukemia (AML), according to ...

Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...

Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...